Summary & Overview
HCPCS M0224: Pemivibart IV Infusion for Pre-Exposure Prophylaxis
HCPCS Level II code M0224 represents the intravenous infusion of pemivibart for pre‑exposure prophylaxis against SARS‑CoV‑2 in certain immunocompromised adults and adolescents. This code bundles the infusion and post‑administration monitoring and matters nationally as clinicians and payers evaluate coverage pathways for targeted prophylactic therapies in high‑risk populations. Payers commonly involved in coverage decisions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what the code denotes, the clinical context for use in moderately to severely immunocompromised patients, and where the infusion is typically delivered. The publication outlines payer coverage considerations and common billing practices, highlights applicable benchmarking elements and coding guidance, and summarizes relevant policy updates affecting administration and reimbursement of pre‑exposure monoclonal antibody infusions. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code M0224 describes the intravenous infusion of pemivibart for pre-exposure prophylaxis in specified adults and adolescents (12 years and older weighing at least 40 kg) with no known SARS‑CoV‑2 exposure who have moderate-to-severe immune compromise due to medical conditions or immunosuppressive therapies. The code includes the drug infusion and required post‑administration monitoring.
Service Type: Intravenous monoclonal antibody infusion for viral pre-exposure prophylaxis
Typical Site of Service: Outpatient infusion center, clinic infusion suite, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of kidney transplant maintained on tacrolimus and mycophenolate presents for scheduled pre-exposure prophylaxis against SARS-CoV-2 using intravenous M0224 (pemivibart). The patient has no known recent COVID-19 exposure and meets age and weight criteria (12 years or older, ≥40 kg) and has documented moderate-to-severe immunocompromise. The clinical workflow begins with outpatient evaluation by the transplant clinic or infectious disease specialist to confirm eligibility, review medication interactions, and obtain informed consent. Baseline vital signs, allergy review, and review of recent SARS-CoV-2 testing and vaccination history are documented. The patient arrives at an infusion center or hospital outpatient infusion suite. A registered nurse verifies identity and orders, establishes IV access, and administers M0224 per product-specific infusion protocol. The code includes the infusion and required post-administration monitoring; typical monitoring includes vital signs at baseline, during infusion as indicated, and for at least 15–60 minutes post-infusion depending on facility protocol and patient risk. Any infusion reactions are managed per facility policies, documented, and may require additional CPT or HCPCS modifiers if emergent services or unplanned care occur. Discharge instructions include signs of delayed reaction and follow-up with the prescribing provider for ongoing prophylaxis planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|